WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 522403
Description: BBS4 is a potent, orally active and selective inducible nitric oxide synthase dimerization inhibitor. BBS4 inhibits the dimerization of iNOS monomers, thus preventing the formation of the dimeric, active form of the enzyme. BBS4 significantly ameliorated adjuvant-induced arthritis in a rat model. BBS4 blocks the formation of the protein-protein interaction present in the dimeric form of iNOS. BBS4 prevents systemic, cardiac, and pulmonary hemodynamic dysfunction in endotoxemic mice.
MedKoo Cat#: 522403
Chemical Formula: C22H24N6O3
Exact Mass: 420.19099
Molecular Weight: 420.47
Elemental Analysis: C, 62.84; H, 5.75; N, 19.99; O, 11.42
Synonym: BBS-4; BBS4; BBS 4; Bardet-Biedl syndrome 4.
IUPAC/Chemical Name: (R)-1-(2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl)-N-(2-(benzo[d][1,3]dioxol-5-yl)ethyl)pyrrolidine-2-carboxamide
InChi Key: LBCGUKCXRVUULK-QGZVFWFLSA-N
InChi Code: InChI=1S/C22H24N6O3/c1-15-11-20(26-22(25-15)27-10-8-23-13-27)28-9-2-3-17(28)21(29)24-7-6-16-4-5-18-19(12-16)31-14-30-18/h4-5,8,10-13,17H,2-3,6-7,9,14H2,1H3,(H,24,29)/t17-/m1/s1
SMILES Code: O=C([C@@H]1N(C2=NC(N3C=CN=C3)=NC(C)=C2)CCC1)NCCC4=CC=C(OCO5)C5=C4
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 420.47 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Ichinose F, Hataishi R, Wu JC, Kawai N, Rodrigues AC, Mallari C, Post JM, Parkinson JF, Picard MH, Bloch KD, Zapol WM. A selective inducible NOS; dimerization inhibitor prevents systemic, cardiac, and pulmonary hemodynamic; dysfunction in endotoxemic mice. Am J Physiol Heart Circ Physiol. 2003; Dec;285(6):H2524-30. Epub 2003 Aug 7. PubMed PMID: 12907425.
2. Davey DD, Adler M, Arnaiz D, Eagen K, Erickson S, Guilford W, Kenrick M,Morrissey MM, Ohlmeyer M, Pan G, Paradkar VM, Parkinson J, Polokoff M, Saionz K, Santos C, Subramanyam B, Vergona R, Wei RG, Whitlow M, Ye B, Zhao ZS, Devlin JJ, Phillips G. Design, synthesis, and activity of 2-imidazol-1-ylpyrimidine derived inducible nitric oxide synthase dimerization inhibitors. J Med Chem. 2007 Mar 22;50(6):1146-57. Epub 2007 Feb 23. PubMed PMID: 17315988.
3. Wei RG, Adler M, Davey D, Ho E, Mohan R, Polokoff M, Tseng JL, Whitlow M, Xu W, Yuan S, Phillips G. 1-(1,3-Benzodioxol-5-ylmethyl)-3-[4-(1H-imidazol-1-yl)phenoxy]-piperidine analogs as potent and selective inhibitors of nitric oxide formation. Bioorg Med Chem Lett. 2007 May 1;17(9):2499-504. Epub 2007 Feb 27. PubMed PMID: 17368901.